SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
THE ANGEL–(BUSINESS WIRE) – Schall Law Firm, a national shareholder rights law firm, is reminding investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. (“AcelRx” or “the Company”) (NASDAQ: ACRX) for violating Sections 10 (b) and 20 (a) of the Securities Exchange Act of 1934 and Rule 10b-5, which were published by the US Securities and Exchange Commission.
Investors who acquired the Company’s securities between March 17, 2020 and February 12, 2021 inclusive (the “Class Period”) are advised to contact the Company before August 9, 2021.
If you are a shareholder who has suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall law firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights free of charge. You can also contact us on the firm’s website at www.schallfirm.com or by email at email@example.com.
In this case, the class has not yet been certified and you will not be represented by a lawyer until certified. If you do nothing, you can remain an absent class member.
According to the lawsuit, the company provided false and misleading information to the market. AcelRx has failed to maintain adequate controls over the disclosure and commercialization of its lead product candidate, DSUVIA. The company made false and misleading claims in its marketing and advertising about the effectiveness and risks associated with DSUVIA. This led to an increased risk of regulatory enforcement actions against the company. Because of these facts, the company’s public statements were false and materially misleading throughout the course period. When the market learned the truth about AcelRx, investors suffered damage.
Join the case to make up for your losses.
The law firm Schall represents investors worldwide and specializes in securities class actions and shareholder disputes.
This news release may be viewed as a solicitation in some jurisdictions under applicable law and ethical rules.